S10 Ep22: CRC Experts Highlight AE Management and Prevention Strategies for TAS-102/Bevacizumab, Regorafenib, and Fruquintinib

from OncLive® On Air · host OncLive® On Air

Strickler, Leung, Dasari, and O'Neill discuss adverse effect monitoring and management with standard agents for patients with colorectal cancer.

Episode metadata supplied by the publisher feed · Published Mar 25, 2024

Embed this episode

Attribution link and audio player

NOW PLAYING

S10 Ep22: CRC Experts Highlight AE Management and Prevention Strategies for TAS-102/Bevacizumab, Regorafenib, and Fruquintinib

0:00 35:25

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Similar Episodes

No similar episodes found.

No similar podcasts found.

This episode is 35 minutes long.

This episode was published on March 25, 2024.

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!